Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Escozine :)
A good read for those newly learning about Medolife rx Aelia QNTA .. or a good reread for longs … nice to be reminded of just how far reaching the potential is for this companies innovative science
https://www.nasdaq.com/press-release/medolife-rx-announces-historic-product-registration-in-dominican-republic-enabling
“This registration not only validates Escozine® as a cancer therapeutic but creates an unbelievable revenue generation opportunity for our company in that the product can be off-label prescribed for treatment of COVID-19 patients as a supportive therapy where vaccination progression has been slow,” said Medolife CEO Dr. Arthur Mikaelian. “Through free trade agreements, we will be able to market Escozine to one of the largest populations in the world. Cancer remains one of the leading causes of death worldwide and estimates have shown between four and five percent of humans will develop cancer in their lifetime. It is our mission to reach these patients with our polarized drug Escozine and improve their quality of life while helping to fight the cancer itself, and we are now registered to do so.”
Let’s see how it looks tomorrow… oddly, if memory serves correctly this stock seems to react a day or two after news… ultimately at least now We, investors, all know what’s what in regards to taking split off the table (hooray for that !!) and aware of all the good things in the pipeline discussed in the CC .. im happy their path thus far is unwavering as far as direction they are headed with products, product development, research, sales both retail and wholesale, FDA etc … clearly the CEO Dr has every intention of his decades of work not being for naught … so many thing are coming together… it’s July, covid is doing crazy things and the Olympics are going .. summer is a weird time … hopefully folks will start seeing the QNTA news / CC and realize the potential that’s about to hit center stage … I’m looking forward to watching QNTA Medolife rx Aelia plans unfurl … also, ticker change will change soon too … exciting stuff
Medolife Rx Cancels Optional Reverse Split Previously Included in Filing !!!
Woohooo!!!
https://www.globenewswire.com/news-release/2021/07/29/2271133/0/en/Medolife-Rx-Cancels-Optional-Reverse-Split-Previously-Included-in-Filing.html
National Library of Medicine: Cytotoxic Effects of Blue Scorpion Venom (Rhopalurus junceus) in a Glioblastoma Cell Line Model
Laura A Lozano-Trujillo et al. Curr Pharm Biotechnol. 2021.
https://pubmed.ncbi.nlm.nih.gov/32679017/
Abstract
Background: Cancer is one of the leading cause of death worldwide. Besides current therapies and treatments to counter cancer, new alternatives are required to diminish the cell proliferation of oncogenic processes.
Methods: One of the most promissory therapy includes the use of blue scorpion venom as a specific cytotoxic agent to kill tumoral cells, including Glioblastoma multiforme.
Objectives: We show evidence of the cytotoxic effect of blue scorpion venom in a cellular model of Glioblastoma multiforme.
Results: Our results demonstrate that 50 µg/ml of scorpion venom is capable to diminish the viability of Glioblastoma populations.
Conclusion: It is possible that the action mechanism could be associated with a loss of membrane integrity. Additionally, some metalloproteinases as MMP2 and MMP9 may also participate in the potential action mechanism.
Keywords: Rhopalurus junceus; blue scorpion; cancer.; cytotoxic effects; glioblastoma; venom.
To the Mooooon hopefully soooon ;)
Looking forward to the Investor Webcast for Tuesday, July 27, 2021
Link below :
https://finance.yahoo.com/news/medolife-rx-schedules-investor-webcast-150400404.html
[{“But to Hawk, these Games are about so much more than landing a few tricks. It is a culmination of years of hard work, and finally being able to see the sport he loves get the spotlight it deserves on the world stage.”}] QNTA dr CEO and Tony Hawk have something in common: perseverance!
https://www.google.com/amp/s/ca.sports.yahoo.com/amphtml/news/tokyo-olympics-2021-watch-tony-hawk-shred-surreal-tokyo-skatepark-ahead-of-sports-olympic-debut-164328557.html
Yes, all hands on deck soon (now maybe) makes sense … if, “if”, they are ready for the full forward push .. below I’ll paste a link to an article along with a KEY point by the ceo, when reading it’s very apparent they WANTED to be under the radar as to be able to quietly gain proof of concept while generating capital and get all their preverbal ducks in a row so to speak … it’s seems like NOW all pillars are sound and foundations laid, research completing status / complete, etc .. don’t get me wrong while im very optimistic I’m also very pragmatic, I’m heavily invested and curious to hear what Tuesday will bring .. but, in the mean time, read the below - the dr ceo has been very transparent with each step along the way thus far, IMO that is … have a great weekend, enjoy the read below - it truly is worth the read or re-read if you’ve seen before …
Looking forward to Tuesday!
———-
I posted the below before on this board, but I feel the excerpt quoted especially addresses the concern over why the company hasn’t been blasting not seeking loud pr thus far …
https://www.google.com/amp/s/www.marketscreener.com/amp/quote/stock/QUANTA-INC-120797064/news/QUANTA-Management-s-Discussion-and-Analysis-of-Financial-Condition-and-Results-of-Operations-for-33348178/
“Creating, producing and selling consumer products was never our primary focus; Quanta's Muscle Rub was simply a means to an end - proof of concept and a revenue driver in a small emerging market as our business model took shape. Fundamentally, Quanta will be a licensing concern designed to collaborate with large brands to improve product quality and the profit margins of existing and new products. But the market needed proof and we chose to start in the under-developed category of CBD because of its speed to market.
Understandably, we met the same initial hurdles every start-up encounters. In addition to simply explaining quantum mechanics, we had no track record of success from a business standpoint. The immediate goal was to prove our model was defensible. Hence, we chose CBD as a launch category. This market provided protection from industry titans that may have felt threatened by such a powerful technology while allowing us to drive profits during R&D.
Over the last two years, we have developed and sold products largely to the medical industry, along with some consumer retail. This effort was designed to drive revenue and to prove the concept of our model: that polarizing a single ingredient can produce a demonstrably superior product that consumers find safe and effective (establish consumer appetite).”
He’s an awesome product ambassador as he truly is known and like among a huge age range of folks AND knowN even by people who know zero about skate boarding. It’s a huge product endorsement win IMO
I’d say he’s 100% youthful .. Have you seen him perform athletically? He can run circles around most of the youth in America these days who sit on couches all day .. check out this 2021 video - id say the term youthful doesn’t even do justice
Tony Hawk is VERY well known … the ad campaign and product push has not even begun yet … also, if someone as youthful and in shape and “cool” as Tony Hawk can admit to needing AND using muscle rub he can make it VERY cool for pretty much all ages to not feel like they are buying old people stuff … the AELIA muscle rub can easily become huge quickly.. but, keep in mind - the muscle rub was always meant to be a conduit used to show proof of concept - and generate revenue while showing the polarization technology works and works well. The ceo is angling for licensing and is eyeing a much much bigger picture than “just cbd rub” … they’ve established strong ties with the Dominican Republic, building a huge scorpion facility both outdoors and a back up indoor facility “as insurance” in case of severe weather / catastrophe, they have patented their science, the venom can be sold retail and used for their own research (making them them self supplied), escozine, and licensing agendas.
They have really laid very strong foundations and pillars if you will to garner success strategically and used by my research what seems to be extremely pragmatic moves towards their goal of building a solid successful company
The Dr CEO didn’t dream this up yesterday.. it’s many many years of research culminating to where we stand right now … so a few extra weeks / days waiting on a pr push from Tony Hawk should not ruffle anyone’s feathers ..
step back, know what you own is what comes to mind .. and let’s hear what they have to say on Tuesday… cheers to all the investors out there - I think it’s hard not to be excited - here’s to continued green day$ ;)
Thanks .. I didn’t bid, I just straight up bought 888 for whatever the sell was … if that helps in any of the figuring out of how sells / buys are being shown
Hmm .. I bought 888 shares today (hour or less ago) I had a little spare change sitting in my account and I like the the number .. did that show as a buy? You have me curious now
They covered quite a lot on their last conference call. The list of topics to discuss is quite impressive - not impressive by volume of topics as much as Impressive list of topics that directly resembles topics share holders have reached out to the company to discuss and or discussed on this board - in my opinion that shows a few things;
They are paying attention to their investors and they seeming have nothing to hide.
Some see confidence as arrogance and confuse the two… I feel from listening to the last call and in all the research I’ve done thus far I’d err to confidence in knowing what they are representing / developing / have patented & proven.
It’s hard not to like QNTA … cheers all that are long … here’s to Green Days
Watching today .. I’m reminiscing about the story of “the little engine that could” …. Goooo QNTA
choo choo $ $ $ ;)
Link to register: Investor Conference Call
Jul 27, 2021 05:00 PM
https://zoom.us/webinar/register/WN_q2EAvbt-QpiDMhYj_ToWFg
11:03a ET 7/21/2021 - Globe Newswire
Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021
Mentioned: QNTA
via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it will hold a webcast and Q&A with the investment community on Tuesday, July 27, at 5 p.m. Eastern Daylight Time. The purpose of this is to answer questions received from the investment community all at one time in an open forum.
On the webcast, Medolife CEO Dr. Arthur Mikaelian and additional members of the Medolife team will discuss recent happenings within the Company, including the following:
-- Social media - i.e., Twitter etc.
-- Update on Investor Relations team
-- Aelia Store
-- Authorized share overview
-- Reverse split overview
-- Nasdaq update
-- Name change and ticker symbol
-- Tony Hawk updates
-- Sports opportunities update
-- Escozine(R) certification of registration number in Dominican Republic
-- Mexico partnership update
-- Opportunities in Vietnam, Cambodia, Colombia
-- US FDA Update
-- Dilution / Reg A / Convertible notes
-- Video being developed
-- Polarization technology can revolutionize the pharmaceutical business with R&D when it comes to venoms of all kinds and other dangerous material
To register for this webcast, please use the below web link.
https://zoom.us/webinar/register/WN_q2EAvbt-QpiDMhYj_ToWFg
If you have questions, please email medolife@cmwmedia.comwith "QNTA Question" in the subject line by 6 p.m. Eastern Daylight Time on Monday, July 26, to ensure all issues are addressed, but there will be a live Q&A also. Dr. Mikaelian will answer as many questions as time will allow. For those unable to participate in the live webcast, an archived version of the webcast will be available in the following days.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company's portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company's lead clinical development programs include Escozine(R), a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company's polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine(R) and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian's polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Tom Nelson
https://ir.quantrx.com/
818-659-8052
Kyle Porter
medolife@cmwmedia.com
858-264-6600
https://ml.globenewswire.com/media/dbe8fad7-b222-45ce-92ef-446b52583d6e/small/quanta-logo-png.png
https://ml.globenewswire.com/media/dbe8fad7-b222-45ce-92ef-446b52583d6e/small/quanta-logo-png.png
Thanks !
Where’s the link for the investor call?
And what time of day is it?
Thanks !!!
Worth the read - here’s a great article link & an excerpt from it https://www.google.com/amp/s/www.marketscreener.com/amp/quote/stock/QUANTA-INC-120797064/news/QUANTA-Management-s-Discussion-and-Analysis-of-Financial-Condition-and-Results-of-Operations-for-33348178/
- as an investor who is long with QNTA, it’s a great re-read to remind oneself why One might be invested and stay long :
“Creating, producing and selling consumer products was never our primary focus; Quanta's Muscle Rub was simply a means to an end - proof of concept and a revenue driver in a small emerging market as our business model took shape. Fundamentally, Quanta will be a licensing concern designed to collaborate with large brands to improve product quality and the profit margins of existing and new products. But the market needed proof and we chose to start in the under-developed category of CBD because of its speed to market.
Understandably, we met the same initial hurdles every start-up encounters. In addition to simply explaining quantum mechanics, we had no track record of success from a business standpoint. The immediate goal was to prove our model was defensible. Hence, we chose CBD as a launch category. This market provided protection from industry titans that may have felt threatened by such a powerful technology while allowing us to drive profits during R&D.
Over the last two years, we have developed and sold products largely to the medical industry, along with some consumer retail. This effort was designed to drive revenue and to prove the concept of our model: that polarizing a single ingredient can produce a demonstrably superior product that consumers find safe and effective (establish consumer appetite).”
Escozine MedolifeRX QNTA would indeed be of great help to many if Buffet is correct - https://www.google.com/amp/s/www.entrepreneur.com/amphtml/376372
“It only makes sense that Escozine® would be effective in mitigating side effects of COVID-19 vaccines as it has been proven to be effective in treating or diminishing the symptoms of the COVID-19 virus itself,” said Medolife CEO Dr. Arthur Mikaelian.
https://www.biospace.com/article/releases/medolife-rx-clinical-observations-demonstrates-effectiveness-of-escozine-in-complementary-use-with-covid-19-vaccines/
Here’s a Link to old - YET very relevant news, great reminder that Medolife rx QNTA has a GREAT relationship with the DR.. if one follows the dots they all seemingly connect together in a pragmatic way with obvious forward looking long term long lasting goals, this agreement was made a few years ago, but shows that the DR respects and supports what QNTA is working to achieve : https://dominicantoday.com/dr/economy/2017/12/19/pact-aims-to-turn-scorpion-venom-into-cancer-fighting-drug/
https://covidnews.app/medolife-rx-announces-donation-of-sting-to-a-healthcare-clinic-in-the-dominican-republic-for-use-in-the-developing-population-of-covid-19-patients/
BURBANK, Calif. , July 14, 2021 (GLOBE NEWSWIRE) – NewMediaWire – Medolife Rx, Inc. (“Medolife”), a global biopharmaceutical company incorporated with R
The basis for receiving the donation is in charge of Dr. Félix Cruz Jiminian, who was one of the main researchers of the society’s safety examination on Escozine® in the Dominican Republic. Data derived from this review were included in the company’s presentation on a new investigational pre-drug (Pre-IND) developed with the U. S. Food and Drug Administration. The U. S. (FDA) and demonstrated that Escozine® was safe and tolerable in all patients who gained the drug candidate. The company’s filing seeks approval of Escozine® as an effective palliative and/or cure for COVID-19 remedy. As initial knowledge has been very positive and with the registration of Escozine in the region as an herbal medicine of choice, the basis plans to be to offer Escozine® administered to patients who have tested positive for COVID-19 and who present moderate to severe symptoms.
“We have been working a lot with Dr. Cruz Jiminian for some time now and we are revered for donating Escozine to his base in hopes of helping many underserved or economically disadvantaged COVID patients in the area,” said Dr. Arthur Mikaelian, CEO of Medolife. “Beyond proceeding with regulatory approval of Escozine with the U. S. FDA. U. S. , We have worked intensively with the Government of the Dominican Republic to determine the effectiveness of Escozine in the fight against COVID-19, waiting for its eventual approval there as well. of our operations are in the Dominican Republic, we want to remain smart grid partners and we believe this donation is a representation of that commitment. We hope that patients who wish to get the drug, and if we can help extra Dr. Jiminian cross and his cause, we plan to do so. “
“We would like to thank Dr. Mikaelian and the entire Medolife team for this incredibly charitable donation to our base,” said Dr. Cruz Jiminian. “I have personally observed the effectiveness of Escozine in fighting viral infections in preclinical studies and since the product is approved as an herbal drug of choice, we are very lucky to be able to give it to patients who want it to the fullest now, as we fight the COVID-19 virus. Our project at the grassroots is to serve those who are underrepresented or who can There are no more beloved remedies and this donation will help in this quest. »
Escozine®, which is composed of scorpion peptides that have been polarized through the Company’s patented process, is Medolife’s leading drug candidate. The company won in mid-June, where it will conduct a new toxicological and pharmacokinetic (PK) study, which is expected to begin in a short period of time.
Beyond the application for approval of Escozine® as a palliative or curative remedy for the COVID-19 virus itself, the Company recently announced that in additional clinical observations, patients who first had strong adverse reactions to COVID-19 vaccines and gained Escozine®, experienced attenuated side effects. These observations led the Company to proceed with the continuation of an additional pilot study on the drug, seeking to demonstrate its effectiveness in reducing the side effects of COVID-19 vaccines.
I agree with your stance Dragon Lady
Tony Hawk; “Because I’m still so active, I’m constantly looking for the most effective products for muscle pain relief, bruising and post skate recovery. Aelia consistently works well for me, so it’s my first choice.” https://aeliastore.com/
I like your thinking …
News July 8, 2021
Medolife Rx Clinical Observations Demonstrates Effectiveness of Escozine in Complementary Use with COVID-19 Vaccines
BURBANK, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife")
https://www.wsj.com/articles/medolife-rx-clinical-observations-demonstrates-effectiveness-of-escozine-in-complementary-use-with-covid-19-vaccines-01625747550?tesla=y
http://drdeanhowell.com/?s=Escozine+
Nice to read about escozine helping people
July 6th was simply a day products were available to ship per the Aelia web page. They had been “pre order” before then … as frustrating as it is to see my account way down … instead of panicking I’m just going over all the things that led me to invest in the first place … and each time I dig I’m more optimistic… obviously with every investment there is risk, and I’m close to all in on QNTA … in the mean time we wait and let their business strategy solidify creating the strong base it’s apparent they are working towards - the mergers, the scorpion ranch, retail products… and don’t forget the scientific patents!!! This stock is valuable based on science alone… at least that’s my opinion, which I’m hoping my opinion is correct
.. do your own DD folks, and share - it’s good to see all angles :)
GLTA
Strategy ;) Worth rereading :
“Having an integrated supply chain of peptides was not only a strategic decision, but it is also a complete differentiator for our company as a global healthcare player,” said Medolife CEO Dr. Arthur Mikaelian. “There has been significant ongoing research into the potential therapeutic benefits of scorpion venom for years and this facility will position us as essentially the world’s largest cultivator and researcher of these highly specific peptides. With the additional scorpions as well as the integrated lab facility, we will be able to meet the demand for our products while controlling costs and furthering our research and development efforts on the scorpion peptides. “
https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/medolife-rx-breaks-ground-lab-120000521.html
I like your thinking! $$$
- The potential is most certainly there … we have to give the company time for them to share with the rest of the world what we as investors already know ;)
They clearly have a long range plan - look at how they are phasing things in and making strategic mergers etc etc
Stay cool everyone - it’s a hot July thus far
Tony Hawk will have the ability to make muscle rub cool ;) it’s not just perceived “old people” who will use the product …
$$$ US8097284B2
United States patent https://patents.google.com/patent/US8097284
Thank you to both of you for sharing! I hope every one had a great / safe Fourth of July!
Happy 4th & scorpion gazing July!
- Besides fireworks, the July sky is optimal time for viewing the scorpion constellation
… Perhaps July is QNTA ‘s month to really shine bright ;)
https://www.google.com/amp/s/www.space.com/amp/29851-scorpius-constellation-july-skywatching.html
paytience …$$$ Rome wasn’t built in a day ;) Medolife rx is growing in phases ..
In addition to the below add in all the partnerships that will facilitate in production of both retail and pharmaceutical skus …
“The reservation upgrades are being done in several phases. In Phase One, which lasted 18 months, Medolife cleared the land and began the deployment of a detailed gridding system that supports the optimization of the venom production process. In Phase Two, the land was further enhanced with the addition of grape arbor foliage, which has been found to dramatically enhance the effectiveness of the scorpion venom. Phase Three will include the addition of an onsite laboratory and scorpion breeding facilities and a helicopter landing pad, as well as upgrades to access roads and addition to helicopter landing pad.”
https://medolife.com/facilities/
Big BUSINE$$ “Discover Powerful Alternatives to Standard Chemo and Radiation, No Side Effects. Immunotherapy Cancer Treatment, High Survival Rates, Financial Aid Options. Read More. Cutting Edge Equipment. Free Phone Consultation”
https://immunotherapyinstitute.com/book-free-consultation/?gclid=CjwKCAjwlYCHBhAQEiwA4K21m3V5fC_2KKIednXf05cs4YZZNS4BfzGlnutdfiACZmzEZxK1OA8slhoCE-4QAvD_BwE